Here are 1-2 brief analogies to describe Pediatrix Medical (MD):

1. DaVita, but for babies' and children's specialized medical care. (Both manage and operate specialized medical services and physician groups for a specific population.)
2. Quest Diagnostics, but for highly specialized doctors and medical teams instead of lab tests. (Both provide critical, specialized medical services that are often outsourced or managed externally for hospitals and healthcare systems.)

• Neonatology Services: Provides specialized medical care for premature and critically ill newborns.
• Maternal-Fetal Medicine: Offers comprehensive care for high-risk pregnancies and complex fetal conditions.
• Pediatric Subspecialty Services: Delivers a wide range of specialized medical care for children across various disciplines, including intensive care, cardiology, and gastroenterology.
• Obstetrics & Gynecology: Offers comprehensive healthcare services for women, including prenatal care, childbirth, and gynecological services.
• Anesthesiology Services: Provides anesthesia administration for surgical and medical procedures, often supporting their women's and children's healthcare services.

Pediatrix Medical Group (symbol: MD) primarily sells its services to other companies, specifically hospitals and other healthcare facilities.

Due to the nature of its business, which involves providing physician services (such as neonatology, maternal-fetal medicine, and other pediatric subspecialties) to a wide network of healthcare providers, Pediatrix does not have a concentration of revenue from any single major customer company or hospital system.

According to their most recent Annual Report on Form 10-K filed with the SEC (for the year ended December 31, 2023), no single hospital, hospital system, or third-party payor accounted for more than 10% of Pediatrix Medical Group's consolidated net patient service revenue or total revenue.

Therefore, while their customers are primarily other companies (hospitals and healthcare systems), there are no individually identifiable "major customers" that meet a common threshold for disclosure as a significant customer.

null

Mark S. Ordan, Chair and Chief Executive Officer

Mark S. Ordan was appointed as Chair and Chief Executive Officer of Pediatrix Medical Group in January 2025. He previously served as CEO from July 2020 to December 2022. Mr. Ordan has a history of leading turnarounds for public companies, including healthcare organizations such as Sunrise Senior Living, Quality Care Properties, and ManorCare. He founded and served as CEO of Fresh Fields Markets, which later merged with Whole Foods Markets, and also founded and was CEO of Quality Care Properties. He has served on the Board of Directors of The Carlyle Group as Lead Independent Director since April 2022.

Kasandra H. Rossi, Executive Vice President, Chief Financial Officer and Treasurer

Kasandra H. Rossi became the Executive Vice President, Chief Financial Officer, and Treasurer of Pediatrix Medical Group on October 1, 2024. She joined the company in 2009 and has held previous financial roles at Office Depot and Republic Services.

Mary Ann E. Moore, Executive Vice President, General Counsel, Chief Administrative Officer and Secretary

Mary Ann E. Moore serves as the Executive Vice President, General Counsel, Chief Administrative Officer, and Secretary for Pediatrix Medical Group.

Greg Neeb, Executive Vice President and Chief Investment & Strategy Officer

Greg Neeb holds the position of Executive Vice President and Chief Investment & Strategy Officer at Pediatrix Medical Group.

Nanette Sanders, Senior Vice President, National Operations

Nanette Sanders is the Senior Vice President of National Operations for Pediatrix Medical Group.

The key risks to Pediatrix Medical (MD) include:

1. Reimbursement and Regulatory Pressures: Pediatrix Medical faces ongoing financial risks due to uncollectible and delayed reimbursements, as well as persistent efforts by payors to control healthcare expenditures through revised coverage and reimbursement policies. The company is frequently involved in inquiries, reviews, audits, and investigations by governmental agencies and private payors regarding its business practices, including compliance with coding, billing, and documentation requirements, which could necessitate repayments. Regulatory changes, such as the No Surprises Act, also pose a threat by aiming to protect patients from unexpected medical bills and can impact the company's relationships with government-sponsored programs (like Medicare and Medicaid) and managed care organizations.
2. Rising Clinical Compensation Costs: The company is challenged by increasing clinical compensation costs, which exert pressure on its margins. This is evident in a reported 2.8% increase in same-unit salary expenses in Q4 2024, highlighting the difficulty in sustaining margin growth amidst labor pressures, particularly in specialties like neonatology.
3. Top-line Revenue Decline from Strategic Divestitures: Pediatrix Medical is undergoing a strategic overhaul that involves shedding lower-margin practices to improve profitability, but this has resulted in an immediate risk of a shrinking top-line revenue. For instance, the full-year 2025 revenue is expected to decline by 5.2% due to portfolio divestitures. While this is a deliberate strategy aimed at long-term profitability and the core business is performing well, it leads to a temporary reduction in overall revenue.

One clear emerging threat for Pediatrix Medical (MD) is the accelerating transition of the healthcare industry towards value-based care models. This shift, driven by payers and government initiatives, moves away from the traditional fee-for-service reimbursement structure (where providers are paid for each service rendered) to models that tie reimbursement to patient outcomes, quality metrics, and cost efficiency. Pediatrix, traditionally operating on a volume-driven model for specialized services in neonatology, maternal-fetal medicine, and pediatric critical care, faces a significant challenge in adapting its operations and financial models to succeed under these new structures. Failure to demonstrate superior outcomes at lower costs or to effectively manage risk under bundled payments or capitated arrangements could severely impact its revenue, profitability, and market position.

Another clear emerging threat stems from the ongoing consolidation and vertical integration within the healthcare provider landscape. As large hospital systems and health networks acquire physician practices and expand their own employed physician groups, they increasingly seek to bring specialized services in-house rather than contract with external groups like Pediatrix. This trend intensifies competition for key hospital contracts and referrals, potentially limiting Pediatrix's growth opportunities and market access. Integrated systems also gain greater negotiating leverage, which can put downward pressure on reimbursement rates for services provided by external groups.

Pediatrix Medical Group (MD) operates in several specialized healthcare markets, primarily focusing on services for women, babies, and children. The addressable markets for their main products and services, predominantly in the U.S., are as follows:

• Neonatology Services: The U.S. neonatal infant care market was valued at approximately USD 925.47 million in 2024 and is projected to reach around USD 1.87 billion by 2034. Globally, the neonatal infant care market was estimated at USD 3.39 billion in 2024 and is predicted to grow to approximately USD 6.7 billion by 2034. The Neonatal Intensive Care Unit (NICU) equipment market, a component of neonatal care, reached USD 4.56 billion in 2025 and is forecast to grow to USD 7.23 billion by 2030.
• Maternal-Fetal Medicine: The global fetal monitoring market, which is closely related to maternal-fetal medicine, was estimated at USD 5.8 billion in 2024 and is expected to grow to USD 11.1 billion by 2034. The U.S. maternal health devices market, which includes fetal monitoring devices, was valued at USD 2.75 billion in 2024 and is expected to reach USD 4.02 billion by 2032.
• Pediatric Subspecialties (including Pediatric Cardiology): The U.S. pediatric cardiology market size is projected to reach US$ 3.59 billion by 2031, growing from US$ 2.54 billion in 2023. North America held approximately 45% of the global pediatric cardiology market share, which was estimated at USD 4.868 billion in 2024 and is projected to grow to USD 7.672 billion by 2035.
• Pediatric Urgent Care Services: The U.S. urgent care centers market size was estimated at USD 34.34 billion in 2024 and is expected to grow to USD 55.07 billion by 2030. Another report valued the U.S. urgent care centers market at USD 75.1 billion in 2023, with a projected compound annual growth rate (CAGR) of 7.5% from 2024 to 2032.
• Pediatric Primary Care: The global Pediatric Primary Care market was valued at US$ 119.7 billion in 2017 and is projected to reach US$ 159.6 billion by the end of 2025. The U.S. pediatric healthcare market, a broader category encompassing primary and specialty care, was valued at USD 4.18 billion in 2024 and is projected to reach approximately USD 9.50 billion by 2034.

Pediatrix Medical (MD) is expected to drive future revenue growth over the next 2-3 years through several key strategies:

1. Enhanced Reimbursement and Payer Dynamics: A significant driver of revenue growth is expected from improved reimbursement-related factors. This includes strong collection activity through efficient revenue cycle management (RCM), an increase in patient acuity (more complex cases requiring higher-value services) in its hospital-based practices, a favorable shift in payer mix towards commercial and other non-government payors, and increased administrative fees from hospital partners.

2. Volume Growth in Specialized Service Lines: The company anticipates revenue growth from increased patient volumes within its core specialized service lines. This includes modest growth in Neonatal Intensive Care Unit (NICU) days and consistent strong volume growth in maternal-fetal medicine. Additionally, Pediatrix expects growth in other hospital-based subspecialties such as newborn nursery, pediatric intensive care, and pediatric hospital services.

3. Strategic Acquisitions and Hospital Partnerships: Pediatrix aims to expand its market presence and service offerings through strategic acquisitions and ongoing partnerships with hospitals. Management has indicated opportunities to acquire or partner with hospital-based practices, leveraging its financial strength to support health systems. The company has already been active in acquiring Neonatal Medicine, Maternal-Fetal Medicine (MFM), and OB hospitalist practices.

4. Technological Advancement and Clinical Leadership: Investments in technology to support clinicians and a focus on clinical leadership are also expected to contribute to revenue growth. Pediatrix emphasizes its "massive clinical scale" and deep research activity, which drive higher quality, innovation, and branding, potentially attracting more patients and partnerships. The company has also launched technology systems like BabySTEPS.

5. Portfolio Restructuring and Operational Efficiencies: While portfolio restructuring may initially lead to a decline in total revenue due to divestitures, it contributes to future revenue growth by focusing on higher-margin, core services and improving operational efficiencies. This strategic realignment aims to enhance the company's margin profile and ensure "same-unit revenue growth" in its most profitable areas.

Share Repurchases

• On August 18, 2025, Pediatrix Medical Group's Board of Directors authorized a new share repurchase program of up to $250 million of the company's outstanding common stock with a three-year term.
• During the third quarter of 2025, the company used $20.9 million to fund share repurchases.
• As of September 30, 2025, $229.1 million remained available for repurchase under the $250 million authorization.

Outbound Investments

• In the third quarter of 2025, Pediatrix used $19.2 million to acquire several neonatology, maternal-fetal medicine (MFM), and OB hospitalist practices.
• The company's strategy includes exploring ongoing opportunities to acquire practices from hospital partners.

Capital Expenditures

• For the third quarter of 2025, Pediatrix funded $5.3 million in capital expenditures.
• The primary focus of capital allocation includes investments in technology and strengthening hospital partnerships.
• Depreciation and amortization expense for the third quarter of 2025 was $5.6 million, primarily reflecting a lower level of capital expenditures at existing units compared to the prior-year period.